Compare ADMA Biologics Inc (ADMA) vs Barrick Gold Corp (B) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Barrick Gold Corp — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while Barrick Gold Corp trades at $35.49 (market cap $61.76B). The key difference: Barrick Gold Corp is far larger — about 29× ADMA Biologics Inc's market cap, and Barrick Gold Corp pays a 1.9% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | B | |
|---|---|---|
Market Cap | $2.13B | $61.76B |
Sector | Health | Basic Materials |
52-Week High | $20.38 | $52.97 |
52-Week Low | $7.60 | $20.73 |
Enterprise Value | $2.20B | $59.35B |
Dividend Yield | — | 1.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Barrick Mining (B) trades at $36.86, down 3.55% over 24 hours, with technical indicators signaling a bearish trend. The company demonstrates strong fundamentals with a P/E of 10.07, net income margin of 32.14%, and consistent earnings beats in recent quarters. Revenue surged to $17.0B in 2025, up from $12.9B in 2024, while cash flow from operations improved to $7.7B. A dividend of $0.18 per share is scheduled for payment on June 15, 2026.
The stock presents a value opportunity with a consensus price target of $51.33, implying 39% upside, supported by 68% analyst buy ratings. Risks include gold price volatility and operational execution challenges. Strong cash flow generation and low debt levels provide a solid foundation for growth, though near-term technical weakness may persist.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Barrick Gold Corp
Barrick Gold Corp is one of the world's largest gold producers, operating mines in North America, South America, Australia, and Africa. The company segments consist of nine gold mines namely Carlin, Cortez, Turquoise Ridge, Pueblo Viejo, Loulo-Gounkoto, Kibali, Veladero, North Mara, and Bulyanhulu. It generates maximum revenue from the Carlin mine segment. Geographically, it derives a majority of revenue from the United States.
Read more on B →
